ASAM TRANEKSAMAT ORAL UNTUK MELASMA PADA ORANG ASIA
-
DOI:
https://doi.org/10.33820/mdvi.v52i3.489Keywords:
asam traneksamat oral, melasma, kulit AsiaAbstract
Melasma merupakan penyakit hiperpigmentasi yang sering ditemukan pada kulit orang Asia. Asam traneksamat (AT) oral merupakan terapi yang inovatif untuk melasma dengan cara kerja multimodal untuk menghambat jalur pigmentasi. AT oral efektif untuk melasma pada orang Asia, dengan dosis 500 mg per hari dalam jangka waktu 8-12 minggu. Penggunaan AT oral aman dan mudah serta memiliki efek samping yang minimal. Penelitian menunjukkan tidak terdapat risiko peningkatan tromboemboli. Sebelum penggunaan AT oral, perlu dilakukan skrining untuk mencari kontraindikasi penggunaan obat tersebut. AT oral dapat digunakan sebagai alternatif pada kasus melasma yang tidak responsif terdapat pengobatan topikal dan dapat diberikan dalam jangka waktu 12 minggu.
Downloads
Download data is not yet available.
References
1. Rodrigues M, Pandya AG. Melasma: clinical diagnosis and management options. Australasian Journal of Dermatology 2015;56(3):151-63.
2. Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. Journal of the American Academy of Dermatology 2011;65(4):699-714.
3. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol 2011;65(4):689-97. doi: 10.1016/j.jaad.2010.12.046
4. Passeron T. Melasma pathogenesis and influencing factors–an overview of the latest research. Journal of the European Academy of Dermatology and Venereology 2013;27:5-6.
5. Mahmoud BH, Ruvolo E, Hexsel CL, et al. Impact of long-wavelength UVA and visible light on melanocompetent skin. Journal of investigative dermatology 2010;130(8):2092-97.
6. Na J, Choi S, Yang S, et al. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. Journal of the European Academy of Dermatology and Venereology 2013;27(8):1035-39.
7. Kang W, Yoon K, Lee ES, et al. Melasma: histopathological characteristics in 56 Korean patients. British journal of dermatology 2002;146(2):228-37.
8. Noh TK, Choi SJ, Chung BY, et al. Inflammatory features of melasma lesions in Asian skin. The Journal of Dermatology 2014;41(9):788-94.
9. Ennes S, Paschoalick R, Alchorne MMDA. A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. Journal of dermatological treatment 2000;11(3):173-79.
10. Bala HR, Lee S, Wong C, et al. Oral tranexamic acid for the treatment of melasma: a review. Dermatologic Surgery 2018;44(6):814-25.
11. Bagherani N. The efficacy of tranexamic acid in the treatment of melasma. Dermatologic Therapy 2015;4(28):265-65.
12. Lukes AS, Freeman EW, Van Drie D, et al. Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study. Women’s Health 2011;7(5):591-98.
13. Hiramoto K, Yamate Y, Sugiyama D, et al. The gender differences in the inhibitory action of UVB?induced melanocyte activation by the administration of tranexamic acid. Photodermatology, Photoimmunology & Photomedicine 2016;32(3):136-45.
14. Wu S, Shi H, Wu H, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthetic plastic surgery 2012;36:964-70.
15. Nijor T. Treatment of melasma with tranexamic acid. Clin Res 1979;13(13):3129-31.
16. Tse TW, Hui E. Tranexamic acid: an important adjuvant in the treatment of melasma. Journal of cosmetic dermatology 2013;12(1):57-66.
17. Maeda K, Naganuma M. Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation. Journal of Photochemistry and Photobiology B: Biology 1998;47(2-3):136-41.
18. Maeda K, Tomita Y. Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte-conditioned medium. Journal of health science 2007;53(4):389-96.
19. Tan AWM, Sen P, Chua SH, Goh BK. Oral tranexamic acid lightens refractory melasma. Australasian Journal of Dermatology 2017;58(3):e105-e08.
20. Cho HH, Choi M, Cho S, Lee JH. Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd: YAG laser. Journal of Dermatological Treatment 2013;24(4):292-96.
21. Lee HC, Thng TGS, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. Journal of the American Academy of Dermatology 2016;75(2):385-92.
22. Callender SLT, Warner G, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J 1970;4(5729):214-16.
23. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57(6):1005-32.
24. Kakar P, Gupta N, Govil P, Shah V. Efficacy and safety of tranexamic acid in control of bleeding following TKR: a randomized clinical trial. Indian journal of anaesthesia 2009;53(6):667-71.
25. Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. European journal of haematology 2002;68(5):307-09.
26. Sundström A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case–control study using the General Practice Research Database. BJOG: An International Journal of Obstetrics & Gynaecology 2009;116(1):91-97.
27. Henry DA, Carless PA, Moxey AJ, et al. Anti?fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane database of systematic reviews 2011(3)
28. Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107(23_suppl_1):I-9-I-16.
2. Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. Journal of the American Academy of Dermatology 2011;65(4):699-714.
3. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol 2011;65(4):689-97. doi: 10.1016/j.jaad.2010.12.046
4. Passeron T. Melasma pathogenesis and influencing factors–an overview of the latest research. Journal of the European Academy of Dermatology and Venereology 2013;27:5-6.
5. Mahmoud BH, Ruvolo E, Hexsel CL, et al. Impact of long-wavelength UVA and visible light on melanocompetent skin. Journal of investigative dermatology 2010;130(8):2092-97.
6. Na J, Choi S, Yang S, et al. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. Journal of the European Academy of Dermatology and Venereology 2013;27(8):1035-39.
7. Kang W, Yoon K, Lee ES, et al. Melasma: histopathological characteristics in 56 Korean patients. British journal of dermatology 2002;146(2):228-37.
8. Noh TK, Choi SJ, Chung BY, et al. Inflammatory features of melasma lesions in Asian skin. The Journal of Dermatology 2014;41(9):788-94.
9. Ennes S, Paschoalick R, Alchorne MMDA. A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. Journal of dermatological treatment 2000;11(3):173-79.
10. Bala HR, Lee S, Wong C, et al. Oral tranexamic acid for the treatment of melasma: a review. Dermatologic Surgery 2018;44(6):814-25.
11. Bagherani N. The efficacy of tranexamic acid in the treatment of melasma. Dermatologic Therapy 2015;4(28):265-65.
12. Lukes AS, Freeman EW, Van Drie D, et al. Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study. Women’s Health 2011;7(5):591-98.
13. Hiramoto K, Yamate Y, Sugiyama D, et al. The gender differences in the inhibitory action of UVB?induced melanocyte activation by the administration of tranexamic acid. Photodermatology, Photoimmunology & Photomedicine 2016;32(3):136-45.
14. Wu S, Shi H, Wu H, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthetic plastic surgery 2012;36:964-70.
15. Nijor T. Treatment of melasma with tranexamic acid. Clin Res 1979;13(13):3129-31.
16. Tse TW, Hui E. Tranexamic acid: an important adjuvant in the treatment of melasma. Journal of cosmetic dermatology 2013;12(1):57-66.
17. Maeda K, Naganuma M. Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation. Journal of Photochemistry and Photobiology B: Biology 1998;47(2-3):136-41.
18. Maeda K, Tomita Y. Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte-conditioned medium. Journal of health science 2007;53(4):389-96.
19. Tan AWM, Sen P, Chua SH, Goh BK. Oral tranexamic acid lightens refractory melasma. Australasian Journal of Dermatology 2017;58(3):e105-e08.
20. Cho HH, Choi M, Cho S, Lee JH. Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd: YAG laser. Journal of Dermatological Treatment 2013;24(4):292-96.
21. Lee HC, Thng TGS, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. Journal of the American Academy of Dermatology 2016;75(2):385-92.
22. Callender SLT, Warner G, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J 1970;4(5729):214-16.
23. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57(6):1005-32.
24. Kakar P, Gupta N, Govil P, Shah V. Efficacy and safety of tranexamic acid in control of bleeding following TKR: a randomized clinical trial. Indian journal of anaesthesia 2009;53(6):667-71.
25. Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. European journal of haematology 2002;68(5):307-09.
26. Sundström A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case–control study using the General Practice Research Database. BJOG: An International Journal of Obstetrics & Gynaecology 2009;116(1):91-97.
27. Henry DA, Carless PA, Moxey AJ, et al. Anti?fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane database of systematic reviews 2011(3)
28. Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107(23_suppl_1):I-9-I-16.
Published
2025-09-30
How to Cite
Arifin, E. D. (2025). ASAM TRANEKSAMAT ORAL UNTUK MELASMA PADA ORANG ASIA: -. Media Dermato-Venereologica Indonesiana, 52(3), 174–177. https://doi.org/10.33820/mdvi.v52i3.489
Issue
Section
Tinjauan Pustaka
License
Copyright (c) 2025 Elly Dainty Arifin
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
